Videos
Watch expert discussions on the key topics in prostate cancer, from emerging treatments to testing and diagnosis.
PLATIPARP
Dr Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, USA) discusses key clinical trials in mCRPC covered at ASCO 2024, focusing on poly-ADP ribose polymerase inhibitors (PARPi). View Video. View transcript.
Dr Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, USA) discusses key clinical trials in mCRPC covered at ASCO 2024, focusing on poly-ADP ribose polymerase inhibitors (PARPi). View Video. View transcript.
PARPi therapy is a relatively recent addition to the armamentarium of treatments for mCRPC. Hear about the clinical implications of PARPi-focused trials presented at ASCO 2024, with Professor Merseburger (University Hospital Schleswig-Holstein, Germany). View Video. View transcript.
How do findings from randomised trials in mCRPC translate to the real world? Dr Agarwal compares and contrasts evidence on olaparib. View Video. View transcript.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.